AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma

RAS/RAF/MEK/ERK1/2 mitogen-activated protein kinase (MAPK) pathway-based treatments, typically combination therapies with inhibitors for oncogenic BRAF V600 (BRAFi) and MEK1/2 (MEKi), are important treatment alternatives to immunotherapy in advanced BRAF-mutated melanoma. However, their benefit is l...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Neoplasia: An International Journal for Oncology Research
المؤلفون الرئيسيون:	Rupesh Paudel, Simon Goller, Stefanie Schwarz, Katharina Meder, Matthias Goebeler, Marc Schmidt
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2026-06-01
الموضوعات:	NRAS-mutant melanoma Therapy resistance MEK5/ERK5 pathway AXL KLF2 KLF4
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S1476558626000308